These 8 drugs could help fight dementia — and they’re already on the market
For decades, dementia research has focused on building new drugs from scratch. That work is paying off, with the first anti-amyloid antibodies now available for early Alzheimer’s disease. But they are expensive, resource‑intensive, and not for everyone. In parallel, scientists are testing a different tactic: repurposing familiar medicines with strong safety records that might prevent dementia, slow its progression, or ease key drivers like inflammation, metabolic dysfunction, and vascular disease.
Below are eight widely used drugs or drug classes with plausible brain benefits and human data suggesting they may help. None are approved to prevent or treat dementia (outside of standard Alzheimer’s symptom drugs like donepezil or memantine), and evidence strength varies from observational studies to small randomized trials. They should not be started, stopped, or switched without talking to a clinician who understands your health history.
1) Metformin (type 2 diabetes)
– Why it might help: Improves insulin signaling, lowers inflammation and oxidative stress, and may promote brain energy efficiency and neurogenesis.
– What we know: Multiple large observational studies link metformin use to lower dementia incidence versus other diabetes drugs. Early randomized studies in people with mild cognitive impairment (MCI) show mixed but encouraging signals on memory and brain metabolism. Several definitive trials are ongoing.
– Caveats: Can cause gastrointestinal side effects and vitamin B12 deficiency; needs monitoring, especially in older adults and those with kidney disease.
2) GLP‑1 receptor agonists (liraglutide, semaglutide)
– Why they might help: Reduce neuroinflammation, improve insulin signaling, enhance brain blood flow and metabolism; in animals, they reduce amyloid and tau pathology.
– What we know: Liraglutide preserved brain glucose metabolism in a small Alzheimer’s study but did not meet its primary cognition endpoint. Two large phase 3 trials of semaglutide in early Alzheimer’s are underway, with results expected mid‑decade. Observational data in diabetes suggest reduced cognitive decline.
– Caveats: Nausea, weight loss, gallbladder issues, and rare pancreatitis. Not yet proven to slow cognitive decline in large trials.
3) Angiotensin receptor blockers (ARBs; e.g., candesartan, losartan, telmisartan)
– Why they might help: Beyond blood pressure control, ARBs that cross the blood–brain barrier may reduce neuroinflammation, improve cerebral perfusion, and protect the blood–brain barrier.
– What we know: Population studies associate ARB use with lower incidence of Alzheimer’s and slower cognitive decline compared with some other antihypertensives. Trials of intensive blood pressure control show less cognitive impairment over time, suggesting vascular risk management is protective.
– Caveats: The brain‑specific benefits remain to be proven in definitive dementia trials. ARBs can lower blood pressure and affect kidney function and potassium.
4) Statins (cholesterol‑lowering drugs)
– Why they might help: Improve vascular health, dampen inflammation, and may influence amyloid processing.
– What we know: Meta‑analyses of millions of patients link statin use with a modestly lower risk of dementia, particularly in those with cardiovascular risk. Randomized trials designed for heart outcomes have not shown clear cognitive benefit in people already diagnosed with Alzheimer’s, but they were not optimized to test that question.
– Caveats: Rare muscle or liver side effects; sporadic reports of reversible memory issues. Benefits likely greatest when used to treat bona fide vascular risk.
5) PDE5 inhibitors (sildenafil, tadalafil)
– Why they might help: Increase nitric oxide signaling and cerebral blood flow; in models, may reduce tau hyperphosphorylation and neuroinflammation.
– What we know: A large database study linked sildenafil use to substantially lower Alzheimer’s incidence, though confounding is possible. Small human studies show improved brain perfusion; early Alzheimer’s trials are underway.
– Caveats: Interact dangerously with nitrates; can lower blood pressure and cause headaches or flushing. Evidence is preliminary.
6) Antiviral therapy targeting herpes simplex virus (valacyclovir)
– Why it might help: Reactivation of HSV‑1 in the brain is a proposed trigger for Alzheimer’s in a susceptible subset; suppressing viral replication could reduce inflammation and amyloid deposition.
– What we know: In national health databases, people with documented HSV infections who received anti‑herpetic drugs had lower subsequent dementia rates than untreated peers. A phase 2 trial of valacyclovir in HSV‑seropositive Alzheimer’s patients has reported feasibility and safety; efficacy results are pending.
– Caveats: Any benefit may be limited to those with HSV involvement. Valacyclovir requires dose adjustment in kidney disease.
7) Low‑dose lithium
– Why it might help: At very low levels, lithium inhibits GSK‑3β, a kinase implicated in tau pathology, and may promote neurogenesis and resilience.
– What we know: Small randomized trials in amnestic MCI reported slower cognitive decline and favorable CSF tau biomarker changes with microdose lithium versus placebo. Ecological data link trace lithium in drinking water to lower dementia rates.
– Caveats: Lithium has a narrow therapeutic window at standard doses; even low‑dose strategies require medical supervision and periodic thyroid and kidney monitoring.
8) Levetiracetam (at sub‑antiepileptic doses)
– Why it might help: Many people with MCI show hippocampal hyperexcitability that correlates with memory problems. Very low‑dose levetiracetam can normalize this network overactivity.
– What we know: Double‑blind crossover studies in amnestic MCI show improved hippocampal network function and modest memory benefits at doses far below those used for epilepsy. Larger, longer trials are in progress.
– Caveats: Can cause irritability, mood changes, or somnolence in some patients; dose and patient selection matter.
What this means for patients and families
– Do not start these medicines solely for brain protection without a personalized discussion of risks, benefits, and alternatives. Evidence ranges from early‑stage to suggestive; none are proven dementia preventives.
– If you already take one for another condition, it may offer a bonus. For example, good control of blood pressure, diabetes, and cholesterol clearly protects the brain over time, regardless of any direct drug effects.
– The fundamentals still matter most: regular aerobic exercise, sleep, hearing correction, smoking cessation, a Mediterranean‑style diet, social engagement, and controlling vascular risks remain the strongest evidence‑based strategies to lower dementia risk.
The road ahead
Repurposing cuts development time and cost, and positive signals are mounting across metabolic, vascular, inflammatory, and neural‑circuit targets. Over the next few years, phase 2–3 trials of semaglutide, valacyclovir, low‑dose lithium, and network‑calming strategies such as levetiracetam should clarify who benefits, by how much, and at what stage of disease. If even a few of these familiar drugs reliably delay cognitive decline, they could make dementia prevention and early intervention more accessible—right now, with medicines we already know how to use safely.
